Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 6/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941818 | 0.87 | IGF1R (0.39) | KMT2AMEN1ATMTRPV4 | |
| SCHEMBL2938325 | 0.87 | IGF1R (0.40) | KMT2AMEN1ATMALDH1A1 | |
| SCHEMBL2940231 | 0.84 | KMT2A (0.48) | KMT2AMEN1ATMGPR139KCNA5 | |
| SCHEMBL2937621 | 0.84 | LIPE (0.42) | LIPECHRM4 | |
| SCHEMBL2939754 | 0.83 | KMT2A (0.48) | KMT2AMEN1ATMGPR139KCNA5 | |
| SCHEMBL2939428 | 0.80 | ACACB (0.38) | — | |
| SCHEMBL3728664 | 0.76 | KMT2A (0.49) | KMT2AMEN1ATMKCNA5ALDH1A1 | |
| SCHEMBL2934005 | 0.74 | LTA4H (0.38) | LIPECHRM4SLC6A4 | |
| SCHEMBL3730580 | 0.73 | KMT2A (0.49) | KMT2AMEN1ATMKCNA5ALDH1A1 | |
| SCHEMBL3724496 | 0.72 | IGF1R (0.41) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825115-B2 | Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| EP-1599464-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2010-09-22 | — | — | EP | disclosed |
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-7354933-B2 | Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate | AVENTIS PHARMA SA (FR) | 2008-04-08 | — | — | US | disclosed |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | PRKG1, PRKACA, CMPK1 | KMT2A 2567/4885MEN1 1754/4885ATM 298/4885 |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | PRKG1, PRKACA, PRKCA | KMT2A 2761/4885MEN1 2077/4885ATM 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.